Foresite Capital Management II LLC cut its position in Zafgen Inc (NASDAQ:ZFGN) by 32.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 449,464 shares of the biopharmaceutical company’s stock after selling 214,316 shares during the period. Zafgen comprises about 0.9% of Foresite Capital Management II LLC’s holdings, making the stock its 10th largest position. Foresite Capital Management II LLC’s holdings in Zafgen were worth $2,095,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Artal Group S.A. purchased a new stake in Zafgen during the fourth quarter worth about $1,590,000. JPMorgan Chase & Co. increased its stake in Zafgen by 937.6% in the first quarter. JPMorgan Chase & Co. now owns 495,743 shares of the biopharmaceutical company’s stock worth $2,311,000 after buying an additional 447,964 shares during the last quarter. State Street Corp increased its stake in Zafgen by 4.2% in the fourth quarter. State Street Corp now owns 352,963 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 14,353 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 89,805 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its stake in Zafgen by 97.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 213,000 shares of the biopharmaceutical company’s stock worth $993,000 after buying an additional 105,000 shares during the last quarter. 50.64% of the stock is currently owned by institutional investors and hedge funds.
Shares of Zafgen Inc (ZFGN) traded up 3.89% during midday trading on Tuesday, hitting $3.74. The company had a trading volume of 109,734 shares. Zafgen Inc has a 12 month low of $2.89 and a 12 month high of $7.13. The company has a 50-day moving average of $4.42 and a 200 day moving average of $4.10. The firm’s market capitalization is $102.37 million.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, analysts expect that Zafgen Inc will post ($2.33) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://sleekmoney.com/foresite-capital-management-ii-llc-sells-214316-shares-of-zafgen-inc-zfgn/1886312.html.
ZFGN has been the topic of several analyst reports. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Wednesday, May 10th. Roth Capital initiated coverage on Zafgen in a research report on Thursday, April 20th. They set a “buy” rating and a $9.00 target price on the stock. Cowen and Company reissued a “hold” rating on shares of Zafgen in a research report on Friday, March 10th. FBR & Co reissued a “marketperform” rating on shares of Zafgen in a research report on Tuesday, March 7th. Finally, ValuEngine downgraded Zafgen from a “sell” rating to a “strong sell” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.92.
In other Zafgen news, insider Dennis D. Kim purchased 10,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was bought at an average cost of $4.40 per share, with a total value of $44,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.30% of the stock is owned by insiders.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen Inc (NASDAQ:ZFGN).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/foresite-capital-management-ii-llc-sells-214316-shares-of-zafgen-inc-zfgn/1886312.html
Receive News & Ratings for Zafgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.